• Revenues for Q1 ‘23 stood at 408 crores as compared to 323 crores in Q1 FY22, a growth of 26%. Revenue split between HCG and Milann stood at 96% and 4% respectively for Q1 FY23.
• Revenues from oncology business grew by 35% on YOY basis to 343 crores and revenue from non-oncology business stood at 58 crores.
• Company AOR stood at 64.6% and AOR for existing versus new centres stood at 64% and 66.1% respectively. Higher Occupancy for new centres is due to only 70% of beds were operational in new centres.
• ARPOB on company level stood at Rs. 38,454 and our ARPOB from existing network stood at Rs. 40,606 and for new centres it stood at Rs.32,968.
• Working on 4 levers for growth – digitization, Cost optimization, growth in medical value travel business, inorganic acquisition.
• Jaipur grew by 263%, revenue from Ranchi grew by 112% and Mumbai grew by 53%. Bangalore centre of excellence grew by 37%. Milann business is also doing well. Revenues have increased by 43% in Q1 FY23 on YOY basis, our new registrations grew by 139%.New centers revenue growth in Milann stood at 70%.
• Management are confident of improving EBITDA margin by 100 to 200 bps over the next 12 to 18 months and profit-making company on a consistent basis from now onwards.
• International business is about 4%. But you would be happy to know that at our center of excellence in Bangalore it’s at 15% of top line and I think we’re just getting started.
• Net debt position excluding capital leases as on 30th June, 2022 stood at 191.5 crores compared to 293.7 crores on 30th June ‘21
• Total plan CAPEX for Ahmedabad is Rs. 85 crores expected date of operations being Q1 FY25 and for Bangalore COE is Rs. 25 crores expected date of operation being Q4 FY24.
• We have two of Mumbai centers as well as Kolkata centers which are greenfield centers for us. We are in process of ramping them up.
• One is an extension center in Whitefield for our center of excellence which is a greenfield project. Our Ahmedabad center of excellence has peaked out in terms of utilization. We are relocating in a newer site with an expanded capacity.
• Capacity of about 1,974 beds right now. We have opersonalised 1,737 beds.
• Maharashtra has only 10% growth because of covid income in base year.
• Tax rate is 34.5%.
• Going forward in the greenfield if we do will be less beds and more outpatient facility, day-care because the whole cancer care is moving towards that.
• Occupancy may increase up to 75%-80%. But more than occupancy the footfall will increase, and the radiation load will increase, the outpatient chemotherapy load will increase, our cost will increase.
• Successful implemented 3.3 MW solar plant at Bangalore facility.
| Subscribe To Our Free Newsletter |
